Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EGFR Inhibitor ABT-414

Known as: ABT-414 
An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, ABT-414 inhibits the… Expand
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
Background: The aim of this study was to prospectively analyse, for the first time worldwide by in vivo clinical confocal… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2018
2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2018
2018
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma
Background We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly… Expand
Highly Cited
2017
Highly Cited
2017
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
Background The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety… Expand
  • figure 2
  • figure 3
Highly Cited
2017
Highly Cited
2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
PurposePatients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
2017
2017
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial
2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is… Expand
Highly Cited
2016
Highly Cited
2016
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2016
2016
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor… Expand
2015
2015
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
2016 Background: GBM remains almost universally fatal and new therapies are needed. The epidermal growth factor receptor (EGFR… Expand
2014
2014
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
2021 Background: Patients (pts) with recurrent GBM have few treatment options and a very poor prognosis. GBM tumors often exhibit… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE